BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1)

September 10, 2015 7:00 AM UTC

Cell and mouse studies suggest combining an ABCG2 inhibitor with topotecan could help treat pediatric brain cancer. Levels of ABCG2 were higher in brain cells from pediatric patients with medulloblastoma or in a mouse model of medulloblastoma than in cells from patients with other brain cancers or normal mice, respectively. In a xenograft mouse model of pediatric brain cancer, an ABCG2 inhibitor tool compound plus topotecan decreased tumor growth and increased survival compared with either agent alone. Next steps could include design and testing of ABCG2 inhibitors alone or in combination with topotecan in pediatric brain cancer models...